| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Medical Genetics, Haartman Institute and Helsinki University Central Hospital, University of Helsinki [W. E-R., S. K.], Department of Pathology, Haartman Institute, University of Helsinki [M. S-R., L. C. A.], FIN-00029 HUCH Helsinki, Finland; Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000 [M. M.]; and Department of Human Genetics, National Research Center, Cairo, Egypt [W. E-R.]
To identify genetic changes related to tumor progression and find out diagnostic and prognostic genetic markers in gastrointestinal stromal tumors (GISTs), 95 tumor samples (24 benign GISTs, 36 malignant primary GISTs, and 35 GIST-metastases) from 60 patients were studied using comparative genomic hybridization. DNA copy number changes were detected in all samples. Benign GISTs had a mean of 2.6 aberrations/sample (losses:gains, 5:1) and significantly fewer DNA copy number changes and fewer gains than malignant primary and metastatic GISTs (P < 0.01). High-level amplifications were not seen in benign GISTs. Malignant primary GISTs had a mean of 7.5 aberrations/tumor (losses:gains, 1.6:1), whereas the mean number of aberrations/metastatic GIST was 9 (losses:gains, 1.8:1). Frequent changes observed in all GIST groups included losses in chromosome arms 1p (51%), 14q (74%), and 22q (53%). Gains and high-level amplifications at 8q and 17q were significantly more frequent in metastatic GISTs (57 and 43%) than in benign GISTs (8 and 0%; P < 0.001) and malignant primary GISTs (33 and 25%; P < 0.05). Gains and high-level amplifications at 20q were only seen in malignant primary and metastatic GISTs (P < 0.01), and gains at 5p were not detected in benign GISTs (P < 0.01). Losses in chromosome arm 9p were never seen in benign tumors (P < 0.001), and they were more frequent in metastatic GISTs than in malignant primary GISTs (63 and 36%; P < 0.05). Losses in 13q were less frequent in benign GISTs than in malignant primary (P < 0.05) and metastatic (P < 0.01) GISTs. Our results show that several DNA copy number changes are related to the behavior of GISTs and can be used as prognostic markers for tumor progression.
This article has been cited by other articles:
|
|
 |
|
  C. Tarn, L. Rink, E. Merkel, D. Flieder, H. Pathak, D. Koumbi, J. R. Testa, B. Eisenberg, M. von Mehren, and A. K. Godwin Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors PNAS, June 17, 2008; 105(24): 8387 - 8392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Suehara, T. Kondo, K. Seki, T. Shibata, K. Fujii, M. Gotoh, T. Hasegawa, Y. Shimada, M. Sasako, T. Shimoda, et al. Pfetin as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Clin. Cancer Res., March 15, 2008; 14(6): 1707 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Janeway, B. Liegl, A. Harlow, C. Le, A. Perez-Atayde, H. Kozakewich, C. L. Corless, M. C. Heinrich, and J. A. Fletcher Pediatric KIT Wild-Type and Platelet-Derived Growth Factor Receptor {alpha} Wild-Type Gastrointestinal Stromal Tumors Share KIT Activation but not Mechanisms of Genetic Progression with Adult Gastrointestinal Stromal Tumors Cancer Res., October 1, 2007; 67(19): 9084 - 9088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Huang, W.-W. Huang, C.-N. Lin, H.-L. Eng, S.-H. Li, C.-F. Li, D. Lu, S.-C. Yu, and C.-Y. Hsiung Immunohistochemical Expression of p16INK4A, Ki-67, and Mcm2 Proteins in Gastrointestinal Stromal Tumors: Prognostic Implications and Correlations with Risk Stratification of NIH Consensus Criteria Ann. Surg. Oncol., December 1, 2006; 13(12): 1633 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Meza-Zepeda, S. H. Kresse, A. H. Barragan-Polania, B. Bjerkehagen, H. O. Ohnstad, H. M. Namlos, J. Wang, B. E. Kristiansen, and O. Myklebost Array Comparative Genomic Hybridization Reveals Distinct DNA Copy Number Differences between Gastrointestinal Stromal Tumors and Leiomyosarcomas. Cancer Res., September 15, 2006; 66(18): 8984 - 8993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Tornillo and L M Terracciano An update on molecular genetics of gastrointestinal stromal tumours. J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Maertens, H. Prenen, M. Debiec-Rychter, A. Wozniak, R. Sciot, P. Pauwels, I. De Wever, J. R. Vermeesch, T. de Raedt, A. De Paepe, et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients Hum. Mol. Genet., March 15, 2006; 15(6): 1015 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Penzel, S Aulmann, M Moock, M Schwarzbach, R J Rieker, and G Mechtersheimer The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated J. Clin. Pathol., June 1, 2005; 58(6): 634 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schneider-Stock, C. Boltze, J. Lasota, B. Peters, C. L. Corless, P. Ruemmele, L. Terracciano, M. Pross, L. Insabato, D. Di Vizio, et al. Loss of p16 Protein Defines High-Risk Patients with Gastrointestinal Stromal Tumors: A Tissue Microarray Study Clin. Cancer Res., January 15, 2005; 11(2): 638 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Corless, J. A. Fletcher, and M. C. Heinrich Biology of Gastrointestinal Stromal Tumors J. Clin. Oncol., September 15, 2004; 22(18): 3813 - 3825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Koon, R Schneider-Stock, M Sarlomo-Rikala, J Lasota, M Smolkin, G Petroni, A Zaika, C Boltze, F Meyer, L Andersson, et al. Molecular targets for tumour progression in gastrointestinal stromal tumours Gut, February 1, 2004; 53(2): 235 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sommer, V. Agosti, I. Ehlers, F. Rossi, S. Corbacioglu, J. Farkas, M. Moore, K. Manova, C. R. Antonescu, and P. Besmer Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase PNAS, May 27, 2003; 100(11): 6706 - 6711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schneider-Stock, C. Boltze, J. Lasota, M. Miettinen, B. Peters, M. Pross, A. Roessner, and T. Gunther High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors J. Clin. Oncol., May 1, 2003; 21(9): 1688 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. DeMatteo The GIST of Targeted Cancer Therapy: A Tumor (Gastrointestinal Stromal Tumor), a Mutated Gene (c-kit), and a Molecular Inhibitor (STI571) Ann. Surg. Oncol., November 1, 2002; 9(9): 831 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Singer, B. P. Rubin, M. L. Lux, C.-J. Chen, G. D. Demetri, C. D.M. Fletcher, and J. A. Fletcher Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors J. Clin. Oncol., September 15, 2002; 20(18): 3898 - 3905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Andersson, H. Sjogren, J. M. Meis-Kindblom, G. Stenman, P. Aman, and L.-G. Kindblom The Complexity of KIT Gene Mutations and Chromosome Rearrangements and Their Clinical Correlation in Gastrointestinal Stromal (Pacemaker Cell) Tumors Am. J. Pathol., January 1, 2002; 160(1): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Allander, N. N. Nupponen, M. Ringner, G. Hostetter, G. W. Maher, N. Goldberger, Y. Chen, J. Carpten, A. G. Elkahloun, and P. S. Meltzer Gastrointestinal Stromal Tumors with KIT Mutations Exhibit a Remarkably Homogeneous Gene Expression Profile Cancer Res., December 1, 2001; 61(24): 8624 - 8628. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
